PURPOSE: To determine if adequate intraocular levels of methotrexate are achieved after intravenous administration. METHODS: After intravenous administration, methotrexate levels were determined in the serum, the anterior chamber, and the cerebrospinal fluids of a patient with recurrent ocular lymphoma. A fluorescence polarization immunoassay was used to make the determinations. RESULTS: At seven hours into a 24-hour intravenous infusion, methotrexate was at cytotoxic level in all samples. At 74 hours, cytotoxic levels were present only in the aqueous humor. CONCLUSION: Sustained cytotoxic ocular methotrexate levels are achievable after systemic administration.
PURPOSE: To determine if adequate intraocular levels of methotrexate are achieved after intravenous administration. METHODS: After intravenous administration, methotrexate levels were determined in the serum, the anterior chamber, and the cerebrospinal fluids of a patient with recurrent ocular lymphoma. A fluorescence polarization immunoassay was used to make the determinations. RESULTS: At seven hours into a 24-hour intravenous infusion, methotrexate was at cytotoxic level in all samples. At 74 hours, cytotoxic levels were present only in the aqueous humor. CONCLUSION: Sustained cytotoxic ocular methotrexate levels are achievable after systemic administration.
Authors: Robert B Nussenblatt; Chi-Chao Chan; Wyndham H Wilson; Jacob Hochman; Michael Gottesman Journal: Ocul Immunol Inflamm Date: 2006-06 Impact factor: 3.070
Authors: Gregory S Vosganian; Saskia Boisot; Kathrin I Hartmann; William R Freeman; Robert W Sharpe; Prabhakar Tripuraneni; Alan Saven Journal: J Neurooncol Date: 2011-05-31 Impact factor: 4.130
Authors: Sapna Gangaputra; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; John H Kempen Journal: Ophthalmology Date: 2009-09-12 Impact factor: 12.079